OCUL vs ZLAB: Which Stock Is the Better Buy?
Ocular Therapeutix, Inc. and Zai Lab Limited side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — OCUL vs ZLAB, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Ocular Therapeutix, Inc. (OCUL) | Zai Lab Limited (ZLAB) | |
|---|---|---|
| Market cap | $1.9B | $1.9B |
| Revenue (latest FY) | $51.95M | $460.16M |
| Net income (latest FY) | $-265.94M | $-175.54M |
| Revenue growth (5y CAGR) | 24.4% | 56.5% |
| Net margin | -511.9% | -38.1% |
| Return on equity | -40.6% | -24.5% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full OCUL vs ZLAB breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open OCUL's full financials → Open ZLAB's full financials →More comparisons
Frequently asked questions
Which is bigger, OCUL or ZLAB?
Zai Lab Limited is larger by market capitalization — $1.9B versus $1.9B.
Which grows faster, OCUL or ZLAB?
Over the last five fiscal years, Zai Lab Limited grew revenue faster — 56.5%/yr versus 24.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
OCUL fundamentals → · ZLAB fundamentals → · All 1,500+ companies → · Free screener →